Tango Therapeutics, Inc. (NASDAQ:TNGX - Get Free Report)'s share price traded down 7.4% on Friday . The stock traded as low as $4.72 and last traded at $4.68. 1,483,483 shares changed hands during mid-day trading, a decline of 6% from the average session volume of 1,580,920 shares. The stock had previously closed at $5.05.
Analysts Set New Price Targets
Separately, HC Wainwright reissued a "buy" rating and issued a $13.00 price objective on shares of Tango Therapeutics in a research note on Monday, April 14th. Six equities research analysts have rated the stock with a buy rating, Based on data from MarketBeat, Tango Therapeutics has an average rating of "Buy" and a consensus target price of $12.20.
Read Our Latest Stock Report on Tango Therapeutics
Tango Therapeutics Stock Up 2.1%
The firm has a market cap of $519.21 million, a P/E ratio of -4.06 and a beta of 1.24. The stock's 50-day simple moving average is $2.09 and its 200 day simple moving average is $2.39.
Tango Therapeutics (NASDAQ:TNGX - Get Free Report) last issued its quarterly earnings results on Monday, May 12th. The company reported ($0.36) EPS for the quarter, missing analysts' consensus estimates of ($0.34) by ($0.02). The firm had revenue of $5.39 million for the quarter, compared to the consensus estimate of $6.73 million. Tango Therapeutics had a negative net margin of 284.42% and a negative return on equity of 49.64%. On average, research analysts forecast that Tango Therapeutics, Inc. will post -1.19 earnings per share for the current fiscal year.
Institutional Trading of Tango Therapeutics
A number of institutional investors have recently bought and sold shares of TNGX. TCG Crossover Management LLC bought a new stake in Tango Therapeutics during the fourth quarter valued at $33,174,000. Boxer Capital Management LLC acquired a new stake in shares of Tango Therapeutics in the 4th quarter valued at about $32,077,000. Gilead Sciences Inc. acquired a new stake in shares of Tango Therapeutics in the 4th quarter valued at about $15,000,000. Farallon Capital Management LLC acquired a new stake in shares of Tango Therapeutics in the 4th quarter valued at about $12,360,000. Finally, Nantahala Capital Management LLC acquired a new stake in shares of Tango Therapeutics in the 4th quarter valued at about $8,666,000. Institutional investors own 78.99% of the company's stock.
About Tango Therapeutics
(
Get Free Report)
Tango Therapeutics, Inc, a biotechnology company, discovers and develops drugs for the treatment of cancer. Its lead program is TNG908, a synthetic lethal small molecule inhibitor of protein arginine methyltransferase 5 that is being developed as a treatment for cancers with methylthioadenosine phosphorylase deletions.
Further Reading
Before you consider Tango Therapeutics, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Tango Therapeutics wasn't on the list.
While Tango Therapeutics currently has a Buy rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Which stocks are likely to thrive in today's challenging market? Enter your email address and we'll send you MarketBeat's list of ten stocks that will drive in any economic environment.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
